All News

Despite the incidence of retinoblastoma remaining consistent throughout Europe, different countries had differing rates of survival.

Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval in January 2023, to treat adult patients who have Alzheimer disease.

During CHEST 2024, Maxine Dexter, MD, Kaiser Permanente, discussed her belief in the vital role of physicians in public health advocacy, drawing from her legislative work on issues as a former Oregon State Representative.

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Outcomes of interest in this study were time from diagnosis to initial prescription fill for an oral multiple myeloma (MM) medication and time from initial diagnosis to receipt of any treatment for MM.

An integrated, rule-based informatics system demonstrated its capacity to leverage electronic health records to streamline the prior authorization process and promote the use of biosimilars.

Patients with endocrine-resistant, HER2-negative, locally advanced or metastatic breast cancer can use the treatment after recurrence or completing adjuvant endocrine therapy.

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Here are 5 key points for pre–breast screening preparation that cover the areas of risk assessment, lifestyle adjustments, understanding screening details, managing anxiety, and open provider communication.

UMass Memorial Health–Harrington Hospital reduced 30-day readmissions for congestive heart failure by 50% using artificial intelligence and remote care teams.

CMS released a preliminary list of 101 generic drugs for its Medicare $2 Drug List Model, which aims to cap out-of-pocket costs at $2 per month for select medications.

Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.

In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in patients with heart failure with reduced ejection fraction (HFrEF), while also addressing prescription barriers for providers.

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

The 41st Association of Cancer Care Centers (ACCC) National Oncology Conference began with a diverse range of poster exhibits, highlighting important initiatives in patient wellness.

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex with men.

The theme of our inaugural regional Institute for Value-Based Medicine® event in Boston was, “Elevating Value in Cancer Care,” and one of the 4 panel discussions focused on the important contributions of pharmacists and the practice of pharmacy to the oncology space.

Vice President Kamala Harris announced her proposal that would require Medicare to cover costs of long-term home care, which would mark a notable expansion of Medicare.

CHEST 2024 late-breaking data showcased the potential of AI-based systems in diagnosing and managing pulmonary embolism.

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of chronic obstructive pulmonary disease (COPD), with better adherence and outcomes among those using single-inhaler triple therapy.

According to KFF’s annual Employer Health Benefits Survey, the average premium for family coverage now stands at $25,572, with workers contributing an average of $6296 annually.

Research from the Heart Failure Society of America Annual Scientific Meeting evaluated remote physiological monitoring for treating systolic heart failure (HF), as well as the impact of a heart transplant allocation system on urban and rural communities.

A study of 555 patients further solidified genotype-phenotype correlations in Duchenne muscular dystrophy (DMD).

Chronic obstructive pulmonary disease (COPD) presents a significant challenge for both patients and health care providers and discussions of effective management strategies took center stage at CHEST 2024 in Boston.

Study compares immediate post-discharge care requirements for respiratory syncytial virus (RSV), influenza, acute myocardial infarction, and stroke.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, discusses key agenda highlights that will be presented at the 2024 AMCP Nexus conference.

CNTN1 and NRXN3 clearly differentiated severe and milder forms of spinal muscular atrophy (SMA).

Three patients with RPE65-related retinopathy showed improved function in both eyes following gene augmentation therapy treatment with voretigene neparvovec.